July 27, 2026 Waters Corporation Unveils the Xevo TQ Absolute XR IVD Mass Spectrometer at ADLM 2026 Annual Meeting Waters Corporation unveiled the Xevo TQ Absolute XR IVD Mass Spectrometer at ADLM 2026, setting new standards in clinical diagnostics with five times greater sensitivity. This innovative system enhances laboratory productivity and reliability in testing, particularly for women's health and toxicology applications.
July 02, 2026 Waters Corporation Schedules Q2 2026 Earnings Conference Call Waters Corporation will hold its Q2 2026 earnings conference call on August 4, 2026, at 8:00 a.m. ET. The call will cover financial results and strategic insights, with a live webcast available for stakeholders.
June 24, 2026 Waters Corporation Partners with IMU Biosciences to Revolutionize Immune Mapping Waters Corporation has partnered with IMU Biosciences to enhance immune mapping using AI and advanced flow cytometry. This collaboration aims to create a universal standard for immune profiling, enabling early disease diagnosis and improving treatment options through comprehensive data analysis.
June 09, 2026 Waters Corporation Unveils Revolutionary Coin Cell Differential Scanning Calorimeter Waters Corporation has launched the Coin Cell Differential Scanning Calorimeter, revolutionizing battery safety testing. This innovative device streamlines workflows by allowing direct testing of intact coin cells, capturing multidimensional data efficiently. With a broad temperature range and enhanced data integrity, it sets a new standard in battery research.
June 08, 2026 Waters Corporation Unveils Revolutionary Reversed-Phase Bioseparation Columns Waters Corporation has unveiled its BioResolve and GTxResolve columns, designed to enhance the separation of impurities in GLP-1 peptides and lipid nanoparticles. These columns promise faster, more reliable analysis for biopharmaceutical developers, addressing long-standing challenges in drug development.
June 03, 2026 Waters Corporation Gains FDA Clearance for BD BACTEC FXI Culture System Waters Corporation has received FDA clearance for the BD BACTEC FXI Culture System, enhancing bloodstream infection diagnostics with reduced detection times. This innovation improves patient outcomes by providing faster and more reliable results in critical care settings.
June 01, 2026 Waters Corporation Unveils Xevo MRT P10 Mass Spectrometer: A Leap Forward in Multiomics Research Waters Corporation unveiled the Xevo MRT P10 Mass Spectrometer at ASMS 2026, offering 20x higher sensitivity and faster analysis for multiomics and biopharmaceutical research. This innovation addresses research challenges and accelerates drug discovery, promising to transform analytical science.
June 01, 2026 Waters Corporation Launches Cyclic IMS P20 Mass Spectrometer: A Breakthrough in Structural and Spatial Omics Waters Corporation has launched the Cyclic IMS P20 Mass Spectrometer, enhancing structural and spatial omics with advanced capabilities for disease detection. This innovative platform promises significant improvements in sensitivity and resolution, enabling researchers to explore critical biological complexities.
May 18, 2026 Waters Corporation to Showcase Leadership at Jefferies Global Healthcare Conference Waters Corporation will present at the Jefferies Global Healthcare Conference on June 3, 2026. CEO Udit Batra will discuss the company's strategic initiatives and innovations in healthcare, highlighting their commitment to improving health outcomes and safety through advanced analytical technologies.
May 05, 2026 Waters Corporation Reports Strong First Quarter 2026 Results Following Major Acquisition Waters Corporation's first quarter of 2026 highlights a strong revenue increase driven by the acquisition of Becton's Biosciences and Diagnostic Solutions. Despite a diluted loss per share, adjusted earnings rose significantly, leading to optimistic future guidance.
April 20, 2026 Waters Corporation Schedules First Quarter 2026 Earnings Conference Call Waters Corporation will hold its Q1 2026 earnings call on May 5, 2026, at 8:30 a.m. ET. Investors can access the live webcast for insights into the company's performance and future strategies.
April 15, 2026 Waters Corporation Achieves CE Mark for BD BACTEC FXI Culture System Waters Corporation's BD BACTEC FXI Culture System has received CE marking, allowing its commercialization in Europe. This innovative system improves the speed and accuracy of bloodstream infection diagnostics, critical for timely patient care.
April 14, 2026 Waters Corporation Unveils Groundbreaking omniDAWN™ MALS Photometer Waters Corporation has launched the omniDAWN™ MALS Photometer, a game-changing instrument for UHPLC and UPLC workflows. It allows for rapid characterization of large molecules, improving efficiency and performance in analytical laboratories. This innovation is set to transform the analysis of complex biologics, supporting advancements in drug discovery and development.
April 08, 2026 Waters Corporation Announces FDA Clearance for Innovative At-Home Cervical Cancer Screening Tool Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit, a groundbreaking tool that allows at-home cervical cancer screening. This innovative solution aims to increase screening rates, improve early detection, and ultimately reduce cervical cancer mortality through enhanced access to essential health services.
March 18, 2026 Waters Corporation Announces Pricing of Senior Notes Offering Waters Corporation has priced a $3.5 billion offering of senior notes through its subsidiary, aimed at managing debt and optimizing capital structure. The proceeds will be used to repay existing indebtedness, enhancing the company's financial position.
March 09, 2026 Waters Corporation Launches ARES-G3 Rheometer: A Game Changer for Materials Science Waters Corporation has launched the ARES-G3 Rheometer, a game-changing tool for materials science that captures 25,000 data points per second, improving efficiency by reducing testing times by up to 80%. Its user-friendly design and advanced technology are set to revolutionize rheology labs worldwide.
February 23, 2026 Waters Corporation to Present at TD Cowen Health Care Conference Waters Corporation's CEO, Udit Batra, will present at the TD Cowen Health Care Conference, showcasing the company's commitment to innovation in life sciences. The event will be webcast live and highlights Waters' leadership in scientific advancements and healthcare solutions.
February 23, 2026 Waters Corporation Reports Strong Performance in 2025 Annual Report Waters Corporation's 2025 annual report reveals a 7% increase in net sales, driven by strong demand across various sectors. With significant growth in Europe and China, the company is well-positioned for future success amid ongoing economic challenges.
February 17, 2026 Waters Corporation Unveils Next-Generation Microflow LC Columns Waters Corporation has launched innovative 1 mm I.D. microflow LC columns using MaxPeak Premier Technology, aimed at improving analytical sensitivity and reducing sample usage. This advancement is set to transform bioanalysis and pharmaceutical development by enhancing performance while minimizing environmental impact.
February 09, 2026 Waters Corporation Completes Strategic Combination with BD's Biosciences & Diagnostic Solutions Waters Corporation has successfully merged with Becton, Dickinson and Company’s Biosciences & Diagnostic Solutions, aiming to lead in life sciences innovation. The merger introduces new leadership and a restructured division model to enhance customer solutions and address global health needs.
February 09, 2026 Waters Corporation Reports Strong Fourth Quarter and Full-Year 2025 Results Waters Corporation reported strong fourth quarter and full-year results for 2025, with a 7% revenue increase and significant growth in non-GAAP EPS. The company's strategic focus on key markets, particularly pharmaceuticals and industrial sectors, underpins its positive outlook for 2026, projecting continued revenue growth and enhanced shareholder value.
January 27, 2026 Waters Corporation Secures Shareholder Approval for BD Combination Waters Corporation has secured 99% shareholder approval for its merger with Becton, Dickinson and Company, a key move to enhance its life sciences capabilities. The merger is set to close on February 9, 2026, following necessary regulatory approvals, positioning Waters as a leader in the sector.
January 20, 2026 Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call Waters Corporation will host its Q4 2025 earnings call on February 12, 2026, at 8:00 a.m. ET. This event will provide insights into the company's financial performance and strategic direction for 2026. Investors can access the live webcast on their Investor Relations website.
December 23, 2025 Waters Corporation Set to Shine at the 44th Annual J.P. Morgan Healthcare Conference Waters Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, led by CEO Udit Batra. The presentation will focus on the company's strategic direction and innovations in healthcare. A live webcast will be available for those unable to attend.
November 11, 2025 Waters Corporation to Participate in Jefferies Global Healthcare Conference Waters Corporation's CEO, Dr. Udit Batra, will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2025. The event will be webcast live, allowing broader access to discussions on the company's strategic direction and innovations in analytical technologies.
November 11, 2025 Waters Corporation Launches Charged Aerosol Detector to Enhance Laboratory Efficiency Waters Corporation has launched the Charged Aerosol Detector (CAD), designed to enhance laboratory efficiency by providing near-universal detection capabilities. This innovation addresses common issues with multi-vendor configurations and integrates seamlessly with Empower Software, promising to improve sample throughput in various analytical fields.
November 04, 2025 Waters Corporation Reports Strong Third Quarter 2025 Financial Results Waters Corporation's Q3 2025 financial results show significant growth with $800 million in sales, an 8% increase year-over-year. Non-GAAP EPS rose 16% to $3.40, driven by strong performance in the pharmaceutical segment and innovative product offerings.
November 04, 2025 Waters Corporation Reports Strong Q3 2025 Results Amid Strategic Acquisitions and Market Challenges Waters Corporation reports an 8% increase in net sales for Q3 2025, driven by strategic acquisitions and strong demand across sectors. Despite challenges, the company remains resilient, with significant growth in recurring revenues and a robust future outlook following a major merger.
October 13, 2025 Waters Corporation Unveils Groundbreaking Charge Detection Mass Spectrometry Technology Waters Corporation has introduced the Xevo Charge Detection Mass Spectrometer (CDMS), a revolutionary tool for biotherapeutics analysis. This technology enables faster and more precise measurements of complex biomolecules, significantly enhancing the development of advanced therapies.
October 01, 2025 Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call Waters Corporation has announced its third quarter 2025 earnings conference call set for November 4, 2025. Investors can access the live call and subsequent webcast to gain insights into the company's financial performance and strategic direction.
August 26, 2025 Waters Corporation to Participate in Wells Fargo Healthcare Conference Waters Corporation will participate in the Wells Fargo Healthcare Conference on September 4, 2025, featuring a chat with CEO Udit Batra. The event will be webcast live, allowing stakeholders to gain insights into the company's healthcare initiatives and strategic direction.
August 04, 2025 Waters Corporation Reports Robust Q2 2025 Financials Amid Strategic Acquisitions Waters Corporation's Q2 2025 financial results show a 9% rise in net sales, fueled by strategic acquisitions, including Halo Labs and a significant merger with BD Biosciences. The company remains focused on innovation and expansion despite market challenges.
August 04, 2025 Waters Corporation Reports Strong Second Quarter 2025 Results Waters Corporation's Q2 2025 results show a 9% increase in sales, driven by instrument replacement trends. The company raised its full-year guidance and highlighted strategic growth initiatives, including a merger with BD Biosciences.
July 11, 2025 Waters Corporation Schedules Second Quarter 2025 Earnings Conference Call Waters Corporation has scheduled its Q2 2025 earnings conference call for August 4th, 2025, at 8:00 a.m. ET. The call will provide crucial insights into the company's financial performance and future strategies. Investors can access a live webcast and a replay until September 2nd.
June 17, 2025 Waters Corporation Sets New Standard in HPLC Technology with Enhanced Software Release Waters Corporation has introduced Alliance iS HPLC System Software version 2.0, enhancing data integrity and traceability for the pharmaceutical industry. The software features improved security measures, reducing human errors by up to 40%, and has received recognition for sustainable practices. This launch marks a significant advancement in operational standards for quality control laboratories.
June 02, 2025 Waters Corporation Launches Groundbreaking Xevo TQ Absolute XR Mass Spectrometer Waters Corporation has unveiled the Xevo TQ Absolute XR Mass Spectrometer, promising unprecedented sensitivity and operational efficiency for high-throughput labs. This model significantly improves upon its predecessor, with features designed for environmental sustainability and robust performance in complex analyses.
May 28, 2025 Waters Corporation Launches BioResolve Protein A Affinity Columns to Revolutionize Antibody Titer Measurement Waters Corporation has launched the BioResolve Protein A Affinity Columns, designed to improve antibody titer measurement in biopharmaceuticals. With enhanced sensitivity and streamlined workflows, this innovation aims to accelerate the development of lifesaving therapies.
May 21, 2025 Waters Corporation Expands Biological Analysis Portfolio with Halo Labs Acquisition Waters Corporation has acquired Halo Labs to strengthen its biological analysis portfolio, particularly in large molecule therapies. The integration of Halo's Aura platform will enhance safety and efficacy in therapeutic development, aligning with Waters' commitment to innovation. This move positions Waters to capitalize on the growing biopharmaceutical market.
May 16, 2025 Waters Corporation Set to Shine at Jefferies Global Healthcare Conference Waters Corporation is poised to present at the Jefferies Global Healthcare Conference, where CEO Udit Batra will discuss the company's healthcare innovations. This event highlights Waters' commitment to enhancing health outcomes through scientific advancements.
May 12, 2025 Waters Corporation Enhances Empower Software with MALS Integration for Biologics Quality Control Waters Corporation has integrated Multi-Angle Light Scattering (MALS) into its Empower Software, enhancing quality control for biopharmaceuticals. This upgrade streamlines data compliance, reduces validation time, and improves analysis efficiency by 20%. The new capabilities will be available from July 2025.
May 06, 2025 Waters Corporation Reports Strong First Quarter 2025 Financial Results Waters Corporation reported $662 million in sales for Q1 2025, a 4% increase year-over-year, and raised its full-year guidance. The company's resilience and growth in the pharmaceutical sector highlight its strong market position.
May 06, 2025 Waters Corporation Reports Strong Q1 2025 Results Amid Global Challenges Waters Corporation announced strong Q1 2025 results, with net sales up 4% to $661.7 million, driven by demand in its Waters™ and TA™ segments. Despite challenges like tariffs and currency fluctuations, the company remains committed to innovation and cost management.
May 06, 2025 Waters Corporation Enhances Biologics Quality Control with Empower Software Integration Waters Corporation has enhanced its Empower Software by integrating Multi-Angle Light Scattering (MALS) capabilities, transforming biologics quality control. This innovation aims to simplify compliance, reduce validation time, and accelerate analysis, ensuring the safety and efficacy of biotherapeutics.
April 08, 2025 Waters Corporation Schedules First Quarter 2025 Earnings Conference Call Waters Corporation has scheduled its Q1 2025 earnings conference call for May 6, 2025, at 8:00 a.m. ET. Stakeholders can access a live webcast or a replay available until June 3, providing insights into the company’s financial health and strategic initiatives.
April 01, 2025 Waters Corporation Expands Alliance iS Bio HPLC Product Line Waters Corporation expands its Alliance iS Bio HPLC product line with a new integrated photodiode array detector, enhancing biopharmaceutical lab efficiency and sustainability. This innovative system improves analytical capabilities, reduces operational risks, and supports compliance with industry standards.
March 07, 2025 Waters Corporation to Participate in Leerink Partners Global Healthcare Conference Waters Corporation will participate in the Leerink Partners Global Healthcare Conference on March 11, 2025, featuring a fireside chat with CEO Udit Batra. The event will showcase the company's strategic initiatives and innovations in analytical technology, with a live webcast available for broader access.
February 25, 2025 Waters Corporation 2024 Annual Report: A Year of Steady Performance Amidst Challenges Waters Corporation's 2024 Annual Report highlights stable revenues and strategic acquisitions, despite challenges in the Chinese market. The report emphasizes the company's commitment to innovation and resilience as it navigates a complex landscape.
February 13, 2025 SWOT Analysis of Waters Corporation in 2025 This SWOT analysis examines Waters Corporation's competitive position in the analytical instruments industry for 2025. It outlines the company's strengths, such as its market position and innovative technologies, while also addressing vulnerabilities and external threats it may face.
February 12, 2025 Waters Corporation Reports Strong Fourth Quarter and Full-Year 2024 Financial Results Waters Corporation reported a 6% sales increase in Q4 2024, driven by strong growth in the pharmaceutical sector and robust geographic performance. The company faces foreign exchange challenges but remains optimistic for 2025, forecasting continued growth.
November 01, 2024 Waters Corporation Q3 2024 Financial Report: Steady Growth Amid Challenges Waters Corporation's Q3 2024 report shows a 4% increase in net sales, driven by strong product demand despite a 2% year-to-date decline. The acquisition of Wyatt Technology enhances its offerings, but challenges remain, particularly in China and operational costs.
July 31, 2024 Waters Corporation Reports Q2 2024 Financial Results: A Mixed Landscape Waters Corporation reported Q2 2024 results showing a decline in net sales to $708.5 million, despite positive growth in recurring revenues. Key insights highlight challenges in major markets, offset by strong performance in India and strategic cost management for future growth.
May 07, 2024 Waters Corporation Reports Q1 2024 Results: Navigating a Challenging Landscape Waters Corporation reported a 7% decline in Q1 2024 net sales, driven by decreased instrument system sales. Despite challenges, recurring revenues increased by 3%, showcasing resilience. The company remains focused on innovation and integrating its recent acquisition.
